Business Context and Reporting Period
This Form 8-K was filed by iBio, Inc. on August 22, 2018, reporting an event that occurred on August 16, 2018. The filing addresses the Company's status regarding its listing on the NYSE American LLC following a previous notice of non-compliance with stockholders' equity standards.
Key Financial Metrics
- Stockholders' Equity Requirement: The NYSE American standard requires listed companies with sustained losses to maintain stockholders' equity of at least $6,000,000.
- Cash on Hand: As of December 31, 2017, the Company held $7.3 million in cash.
- Recent Capital Raises:
- June 26, 2018: Closed a public offering of 4,350,000 common shares and convertible preferred stock.
- July 12, 2018: Sold 1,500,000 additional common shares via over-allotment exercise.
- Total Gross Proceeds: Approximately $17,350,000 from the combined offerings.
- Other Liquidity Sources: Future sales under a purchase agreement with Lincoln Park Capital Fund, LLC, license/collaboration proceeds, and operations of subsidiary iBio CDMO LLC.
Material Changes and Listing Status
On August 16, 2018, the NYSE American accepted the Company's plan to regain compliance with Section 1003(a)(iii) of the Company Guide. The Exchange granted a plan period extending through December 6, 2019. This acceptance follows a June 8, 2018 notification that the Company was not in compliance due to stockholders' equity falling below $6,000,000 combined with sustained losses.
The listing of the Company's common stock continues without immediate interruption, subject to quarterly monitoring. Failure to meet the plan's progress or the equity standard by December 6, 2019, will trigger delisting proceedings.
Outlook, Risks, and Management Commentary
Management believes the combination of recent capital raise proceeds ($17.35 million), existing cash ($7.3 million), and anticipated future revenue streams will be sufficient to maintain the required stockholders' equity through the end of the plan period. The primary risk identified is the potential for delisting if the Company fails to demonstrate progress consistent with the approved plan or fails to meet the equity threshold by the December 6, 2019 deadline.
Investor Verification Checklist
- Verify the Company's current stockholders' equity balance to ensure it remains above the $6,000,000 threshold.
- Monitor quarterly reports for progress updates against the specific initiatives outlined in the compliance plan accepted by the Exchange.
- Confirm the status of the purchase agreement with Lincoln Park Capital Fund, LLC and the operational performance of iBio CDMO LLC as liquidity sources.
- Review future 8-K filings for any notices of delisting proceedings should the Company fail to meet the December 6, 2019 deadline.